193 related articles for article (PubMed ID: 21898354)
1. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.
Solomon DH; Mercer E; Kavanaugh A
Arthritis Rheum; 2012 Jan; 64(1):21-32. PubMed ID: 21898354
[No Abstract] [Full Text] [Related]
2. Are we content that risk of cancer is not appreciably increased after tumor necrosis factor inhibitor use? Comment on the article by Solomon et al.
Yazici H; Yazici Y
Arthritis Rheum; 2012 Jul; 64(7):2414; author reply 2414-5. PubMed ID: 22549846
[No Abstract] [Full Text] [Related]
3. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis.
Jiménez FG; Colmenero JD; Irigoyen MV
J Infect; 2005 May; 50(4):370-1. PubMed ID: 15845443
[No Abstract] [Full Text] [Related]
4. Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?
Bongartz T; Orenstein R
Nat Rev Rheumatol; 2009 Jul; 5(7):361-3. PubMed ID: 19568250
[No Abstract] [Full Text] [Related]
5. Adalimumab-induced neutropenia in a patient with rheumatoid arthritis.
Ottaviani S; Cerf-Payrastre I; Kemiche F; Pertuiset E
Joint Bone Spine; 2009 May; 76(3):312-3. PubMed ID: 19289296
[No Abstract] [Full Text] [Related]
6. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
Chaves Y; Duarte G; Ben-Said B; Tebib J; Berard F; Nicolas JF
Dermatology; 2008; 217(4):380. PubMed ID: 18849606
[No Abstract] [Full Text] [Related]
7. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
Nagashima T; Minota S
J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
[No Abstract] [Full Text] [Related]
8. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
Baltà-Cruz S; Alsina-Glbert M; Mozos-Rocafort A; Cervera C; Colomo-Saperas L; Del Río A; Estrach-Panella T
Acta Derm Venereol; 2009; 89(4):432-3. PubMed ID: 19688168
[No Abstract] [Full Text] [Related]
9. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis.
Day R
Lancet; 2002 Feb; 359(9306):540-1. PubMed ID: 11867103
[No Abstract] [Full Text] [Related]
10. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
[No Abstract] [Full Text] [Related]
11. Extraarticular rheumatoid arthritis and drug-induced syndromes: understanding the role of tumor necrosis factor inhibitors.
Bruyn GA
J Rheumatol; 2004 Jul; 31(7):1461; author reply 1462. PubMed ID: 15229972
[No Abstract] [Full Text] [Related]
12. [Serious lung disease in RA and TNF-blockade--is there a connection?].
Turesson C; Jacobsson L; Saxne T; Geborek P
Lakartidningen; 2006 Feb 1-7; 103(5):308; author reply 308-9. PubMed ID: 16512575
[No Abstract] [Full Text] [Related]
13. Comments on Falgarone et al. editorial entitled "TNFalpha antagonists in rheumatoid arthritis patients seen in everyday practice".
Legoff P
Joint Bone Spine; 2008 Oct; 75(5):626; author reply 626. PubMed ID: 18805723
[No Abstract] [Full Text] [Related]
14. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Hochman D; Wolff B
JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
[No Abstract] [Full Text] [Related]
15. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Callegari PE; Schaible TF; Boscia JA
JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
[No Abstract] [Full Text] [Related]
16. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Costenbader KH; Glass R; Cui J; Shadick N
JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
[No Abstract] [Full Text] [Related]
17. Infliximab: additional safety data from an open label study.
Daniel CL; Moreland LW
J Rheumatol; 2002 Apr; 29(4):647-9. PubMed ID: 11950000
[No Abstract] [Full Text] [Related]
18. Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare?
Aslanidis S; Pyrpasopoulou A; Douma S; Petidis K
Arthritis Rheum; 2008 Jan; 58(1):327-8. PubMed ID: 18163500
[No Abstract] [Full Text] [Related]
19. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
Gabriel SE
Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
[No Abstract] [Full Text] [Related]
[Next] [New Search]
